() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

News

PreveCeutical signs Research and Option Agreement with UniQuest Pty Limited for Developing Dual-Gene Therapy Treatment for Diabetes and Obesity

PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV) announces, further to its news release dated April 13, 2017, that it has entered into a research and option agreement through an agreement made effective as of July 14, 2017 (the “Research Agreement”) between its wholly-owned subsidiary, PreveCeutical Medicals Holdings Inc., and UniQuest Pty Limited (“UniQuest”), the main commercialization company for the University of Queensland (“UQ”), to conduct a research program (the “Research Program”) focused on the development of Smart-siRNAs for the treatment of diabetes and obesity. This will be the third research and option agreement between PreveCeutical and UniQuest.
Read more

PreveCeutical Signs Research and Development Agreement with UniQuest Pty Limited for Extraction, Formulation and Ex Vivo Evaluation of Cannabinoids (“CBD”s) for Delivery via Sol-Gels.

PreveCeutical Medical Inc. (“PMI”) a health and wellness company focused on utilising nature and science for the benefit of health-conscious consumers, is pleased to announce that it has signed a research and development agreement effective April 22, 2017 (the "Agreement") with UniQuest Pty Limited (“UniQuest”) for conducting a research program (the "Research Program") for the extraction, formulation and ex vivo evaluation of cannabinoids (CBDs) for local/direct nose-to-brain delivery via Sol-Gels. UniQuest is the main commercialisation company for The University of Queensland (“UQ”).
Read more

PreveCeutical Signs Research and Development Agreement with UniQuest Pty Limited for Development of Caribbean Blue Scorpion Venom-Derived Natural & Synthetic Peptides

PreveCeutical Medical Inc. (“PMI”) a health and wellness company focused on utilizing nature and science for the benefit of health-conscious consumers, is pleased to announce that it signed a research and option agreement (the "Agreement") with UniQuest Pty Limited (“UniQuest”) for conducting a research program (the "Research Program") for the development of Scorpion Venom-Derived Natural & Synthetic Peptides. UniQuest is the main commercialisation company for the University of Queensland (“UQ”).
Read more
Get $50 in free trades.